Publications
-
A distinct evolution of the T cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease.
Meyer EH,
Hsu AR, Liliental J, Löhr A, Florek M, Zehnder JL, Strober S, Lavori P, Miklos DB, Johnson DS, Negrin RS.
Blood.
2013
-
Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity.
Müller AM,
Shashidhar S, Küpper NJ, Kohrt HE, Florek M, Negrin RS, Brown JM, Shizuru JA.
Proc Natl Acad Sci U S A.
2012;
109
(15):
5820-5
-
Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells.
Müller AM,
Kohrt HE, Cha S, Laport G, Klein J, Guardino AE, Johnston LJ, Stockerl-Goldstein KE, Hanania E, Juttner C, Blume KG, Negrin RS, Weissman IL, Shizuru JA.
Biol Blood Marrow Transplant.
2012;
18
(1):
125-33
-
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.
Arai S,
Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB.
Blood.
2012;
119
(25):
6145-54
-
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.
Gill S,
Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, Florek M, Gibbs KD, Tate K, Ritchie DS, Negrin RS.
Blood.
2012;
119
(24):
5758-68
-
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation.
Johnston L,
Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R.
Bone Marrow Transplant.
2012;
47
(4):
581-8
-
Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
Laport GG,
Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS.
Biol Blood Marrow Transplant.
2011;
17
(11):
1679-87
-
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR,
Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG.
Biol Blood Marrow Transplant.
2011;
17
(7):
1051-7
-
CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD.
Dutt S,
Baker J, Kohrt HE, Kambham N, Sanyal M, Negrin RS, Strober S.
Blood.
2011;
117
(11):
3230-9
-
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY.
Naik S,
Wong R, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Blume K, Negrin R, Johnston L.
Bone Marrow Transplant.
2011;
46
(2):
192-9
-
Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism.
Leveson-Gower DB,
Olson JA, Sega EI, Luong RH, Baker J, Zeiser R, Negrin RS.
Blood.
2011;
117
(11):
3220-9
-
Natural and expanded CD4(+)CD25(+) regulatory T cells in bone marrow transplantation.
Colonna L,
Sega EI, Negrin RS.
Biol Blood Marrow Transplant.
2011;
17
(1 Suppl):
S58-62
-
Role of regulatory T cell populations in controlling graft vs host disease.
Negrin RS,
Best Pract Res Clin Haematol.
2011;
24
(3):
453-7
-
Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells.
Pearl JI,
Lee AS, Leveson-Gower DB, Sun N, Ghosh Z, Lan F, Ransohoff J, Negrin RS, Davis MM, Wu JC.
Cell Stem Cell.
2011;
8
(3):
309-17
-
Biology and clinical effects of natural killer cells in allogeneic transplantation.
Benjamin JE,
Gill S, Negrin RS.
Curr Opin Oncol.
2010;
22
(2):
130-7
-
CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells.
Dürr C,
Pfeifer D, Claus R, Schmitt-Graeff A, Gerlach UV, Graeser R, Krüger S, Gerbitz A, Negrin RS, Finke J, Zeiser R.
Cancer Res.
2010;
70
(24):
10170-81
-
Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells.
Contag CH,
Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachireddy P, Felsher DW, Thorne SH.
Cancer Res.
2010;
70
(23):
9837-45
-
Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.
Weng WK,
Negrin RS, Lavori P, Horning SJ.
J Clin Oncol.
2010;
28
(2):
279-84
-
Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure.
Benjamin JE,
Chen GL, Cao TM, Cao PD, Wong RM, Sheehan K, Shizuru JA, Johnston LJ, Negrin RS, Lowsky R, Laport GG.
Bone Marrow Transplant.
2010;
45
(2):
303-9
-
NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
Olson JA,
Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS.
Blood.
2010;
115
(21):
4293-301
-
Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
Arai S,
Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ.
Biol Blood Marrow Transplant.
2010;
16
(8):
1145-54
-
Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells.
Ai WZ,
Hou JZ, Zeiser R, Czerwinski D, Negrin RS, Levy R.
Int J Cancer.
2009;
124
(1):
239-44
-
Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses.
Gill S,
Olson JA, Negrin RS.
Biol Blood Marrow Transplant.
2009;
15
(7):
765-76
-
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.
Kohrt HE,
Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R.
Blood.
2009;
114
(5):
1099-109
-
Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation.
Olson JA,
Zeiser R, Beilhack A, Goldman JJ, Negrin RS.
J Immunol.
2009;
183
(5):
3219-28
-
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.
Zeiser R,
Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, Hou JZ, Negrin RS.
Blood.
2008;
111
(1):
453-62
-
In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.
Nishimura R,
Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, Karimi M, Negrin RS.
Blood.
2008;
112
(6):
2563-74
-
Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen.
Laport GG,
Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, Wong RM, Negrin RS, Blume KG, Forman SJ.
Blood.
2008;
112
(3):
903-9
-
Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
Chen AI,
McMillan A, Negrin RS, Horning SJ, Laport GG.
Biol Blood Marrow Transplant.
2008;
14
(7):
741-7
-
Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation in vivo.
Björck P,
Beilhack A, Herman EI, Negrin RS, Engleman EG.
J Immunol.
2008;
181
(6):
3811-7
-
Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs.
Beilhack A,
Schulz S, Baker J, Beilhack GF, Nishimura R, Baker EM, Landan G, Herman EI, Butcher EC, Contag CH, Negrin RS.
Blood.
2008;
111
(5):
2919-28
-
The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation.
Nguyen VH,
Shashidhar S, Chang DS, Ho L, Kambham N, Bachmann M, Brown JM, Negrin RS.
Blood.
2008;
111
(2):
945-53
-
Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease.
Zeiser R,
Nguyen VH, Hou JZ, Beilhack A, Zambricki E, Buess M, Contag CH, Negrin RS.
Blood.
2007;
109
(5):
2225-33
-
Host-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease.
Zeiser R,
Zambricki EA, Leveson-Gower D, Kambham N, Beilhack A, Negrin RS.
Biol Blood Marrow Transplant.
2007;
13
(12):
1427-38
-
In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation.
Nguyen VH,
Zeiser R, Dasilva DL, Chang DS, Beilhack A, Contag CH, Negrin RS.
Blood.
2007;
109
(6):
2649-56
-
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.
Zeiser R,
Youssef S, Baker J, Kambham N, Steinman L, Negrin RS.
Blood.
2007;
110
(13):
4588-98
-
Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic cell transplantation.
Zeiser R,
Beilhack A, Negrin RS.
Curr Stem Cell Res Ther.
2006;
1
(2):
203-12
-
Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK,
Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH, Lum LG, Negrin RS.
Clin Cancer Res.
2006;
12
(6):
1859-67
-
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY,
Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.
Biol Blood Marrow Transplant.
2006;
12
(7):
703-11
-
In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease.
Negrin RS,
Contag CH.
Nat Rev Immunol.
2006;
6
(6):
484-90
-
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production.
Zeiser R,
Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, Contag CH, Negrin RS.
Blood.
2006;
108
(1):
390-9
-
Role of naturally arising regulatory T cells in hematopoietic cell transplantation.
Nguyen VH,
Zeiser R, Negrin RS.
Biol Blood Marrow Transplant.
2006;
12
(10):
995-1009
-
Synergistic antitumor effects of immune cell-viral biotherapy.
Thorne SH,
Negrin RS, Contag CH.
Science.
2006;
311
(5768):
1780-4
-
A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
Leemhuis T,
Wells S, Scheffold C, Edinger M, Negrin RS.
Biol Blood Marrow Transplant.
2005;
11
(3):
181-7
-
Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation.
Schimmelpfennig CH,
Schulz S, Arber C, Baker J, Tarner I, McBride J, Contag CH, Negrin RS.
Am J Pathol.
2005;
167
(5):
1321-31
-
Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system.
Shizuru JA,
Negrin RS, Weissman IL.
Annu Rev Med.
2005:
56
509-38
-
In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets.
Beilhack A,
Schulz S, Baker J, Beilhack GF, Wieland CB, Herman EI, Baker EM, Cao YA, Contag CH, Negrin RS.
Blood.
2005;
106
(3):
1113-22
-
Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation.
Cao YA,
Bachmann MH, Beilhack A, Yang Y, Tanaka M, Swijnenburg RJ, Reeves R, Taylor-Edwards C, Schulz S, Doyle TC, Fathman CG, Robbins RC, Herzenberg LA, Negrin RS, Contag CH.
Transplantation.
2005;
80
(1):
134-9
-
Protective conditioning for acute graft-versus-host disease.
Lowsky R,
Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S.
N Engl J Med.
2005;
353
(13):
1321-31
-
Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells.
Karimi M,
Cao TM, Baker JA, Verneris MR, Soares L, Negrin RS.
J Immunol.
2005;
175
(12):
7819-28
-
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M,
Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS.
Nat Med.
2003;
9
(9):
1144-50
-
Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.
Edinger M,
Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS.
Blood.
2003;
101
(2):
640-8
-
Advancing animal models of neoplasia through in vivo bioluminescence imaging.
Edinger M,
Cao YA, Hornig YS, Jenkins DE, Verneris MR, Bachmann MH, Negrin RS, Contag CH.
Eur J Cancer.
2002;
38
(16):
2128-36
-
Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice.
Verneris MR,
Baker J, Edinger M, Negrin RS.
J Clin Immunol.
2002;
22
(3):
131-6
-
Understanding immune cell trafficking patterns via in vivo bioluminescence imaging.
Mandl S,
Schimmelpfennig C, Edinger M, Negrin RS, Contag CH.
J Cell Biochem Suppl.
2002:
39
239-48
-
Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C,
Kornacker M, Scheffold YC, Contag CH, Negrin RS.
Cancer Res.
2002;
62
(20):
5785-91
-
Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence.
Negrin RS,
Edinger M, Verneris M, Cao YA, Bachmann M, Contag ChH.
Ann Hematol.
2002:
81 Suppl 2
S44-5
-
Bioluminescence imaging of lymphocyte trafficking in vivo.
Hardy J,
Edinger M, Bachmann MH, Negrin RS, Fathman CG, Contag CH.
Exp Hematol.
2001;
29
(12):
1353-60
-
CD31 mismatching affects marrow transplantation outcome.
Grumet FC,
Hiraki DD, Brown BWM, Zehnder JL, Zacks ES, Draksharapu A, Parnes J, Negrin RS.
Biol Blood Marrow Transplant.
2001;
7
(9):
503-12
-
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
Stuart MJ,
Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ, Shizuru JA, Long GD, Blume KG, Stockerl-Goldstein KE.
Biol Blood Marrow Transplant.
2001;
7
(10):
552-60
-
Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.
Verneris MR,
Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA.
Biol Blood Marrow Transplant.
2001;
7
(10):
532-42
-
Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production.
Baker J,
Verneris MR, Ito M, Shizuru JA, Negrin RS.
Blood.
2001;
97
(10):
2923-31
-
Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.
Alvarnas JC,
Linn YC, Hope EG, Negrin RS.
Biol Blood Marrow Transplant.
2001;
7
(4):
216-22
-
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial.
Horning SJ,
Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD, Brown BW, Blume KG.
Blood.
2001;
97
(2):
404-9
-
High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.
Cao TM,
Horning S, Negrin RS, Hu WW, Johnston LJ, Taylor TL, Shizuru JA, Hoppe RT, Brown BW, Blume KG, Stockerl-Goldstein KE.
Biol Blood Marrow Transplant.
2001;
7
(5):
294-301
-
Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM,
Kusnierz-Glaz C, Valone F, Stockerl-Goldstein KE, Hu WW, Johnston L, Blume KG, Strober S, Negrin RS.
Cancer.
2001;
91
(12):
2205-13
-
Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells.
Kornacker M,
Verneris MR, Kornacker B, Scheffold C, Negrin RS.
Immunol Lett.
2001;
76
(3):
169-73
-
Use of reporter genes for optical measurements of neoplastic disease in vivo.
Contag CH,
Jenkins D, Contag PR, Negrin RS.
Neoplasia.
2000 Jan-Apr;
2
(1-2):
41-52
-
CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies.
Lopez RD,
Xu S, Guo B, Negrin RS, Waller EK.
Blood.
2000;
96
(12):
3827-37
-
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells.
Stockerl-Goldstein KE,
Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW, Johnston LF, Long GD, Strober S, Wong RM, Feiner RH, Kobler S, Negrin RS.
Biol Blood Marrow Transplant.
2000;
6
(5):
506-12
-
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
Hu WW,
Negrin RS, Stockerl-Goldstein K, Johnston LJ, Shizuru JA, Wong RM, Chao NJ, Long GD, Feiner RH, Blume KG.
Biol Blood Marrow Transplant.
2000;
6
(1):
58-69
-
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
Alvarnas JC,
Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, Stockerl-Goldstein K, Tierney K, Wong R, Blume KG, Chao NJ.
Biol Blood Marrow Transplant.
2000;
6
(3A):
352-8
-
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Cao TM,
Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor TL, Rizk NW, Wong RM, Blume KG, Hu WW.
Biol Blood Marrow Transplant.
2000;
6
(4):
387-94
-
Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis.
Verneris MR,
Kornacker M, Mailänder V, Negrin RS.
Cancer Immunol Immunother.
2000;
49
(6):
335-45
-
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Johnston LJ,
Stockerl-Goldstein KE, Hu WW, Negrin RS, Hoppe RT, Blume KG, Horning SJ.
Biol Blood Marrow Transplant.
2000;
6
(5A):
555-62
-
Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer.
Negrin RS,
Atkinson K, Leemhuis T, Hanania E, Juttner C, Tierney K, Hu WW, Johnston LJ, Shizurn JA, Stockerl-Goldstein KE, Blume KG, Weissman IL, Bower S, Baynes R, Dansey R, Karanes C, Peters W, Klein J.
Biol Blood Marrow Transplant.
2000;
6
(3):
262-71
-
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW,
Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG.
Clin Cancer Res.
1999;
5
(11):
3411-8
-
Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.
Ross M,
Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Forman SJ, Blume KG, Chao NJ.
Biol Blood Marrow Transplant.
1999;
5
(5):
285-91
-
Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation.
Dickson TM,
Kusnierz-Glaz CR, Blume KG, Negrin RS, Hu WW, Shizuru JA, Johnston LL, Wong RM, Stockerl-Goldstein KE.
Biol Blood Marrow Transplant.
1999;
5
(5):
299-305
-
Noninvasive assessment of tumor cell proliferation in animal models.
Edinger M,
Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, Contag CH.
Neoplasia.
1999;
1
(4):
303-10
-
Visualizing the kinetics of tumor-cell clearance in living animals.
Sweeney TJ,
Mailänder V, Tucker AA, Olomu AB, Zhang W, Cao Ya, Negrin RS, Contag CH.
Proc Natl Acad Sci U S A.
1999;
96
(21):
12044-9
-
Engraftment of chronic myeloid leukemia in SCID mice.
Hoyle CF,
Negrin RS.
Hematol Oncol.
1998;
16
(3):
87-100
-
Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C,
Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS.
Blood.
1998;
92
(9):
3318-27
-
Minimal residual disease.
Negrin RS,
Curr Opin Hematol.
1998;
5
(6):
488-93
-
Cellular immunotherapy following autologous hematopoietic progenitor cell transplantation.
Lu PH,
Negrin RS.
Biol Blood Marrow Transplant.
1997;
3
(3):
113-21
-
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD,
Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG.
Biol Blood Marrow Transplant.
1997;
3
(6):
324-30
-
Granulocyte colony-stimulating factor-induced comobilization of CD4- CD8- T cells and hematopoietic progenitor cells (CD34+) in the blood of normal donors.
Kusnierz-Glaz CR,
Still BJ, Amano M, Zukor JD, Negrin RS, Blume KG, Strober S.
Blood.
1997;
89
(7):
2586-95
-
High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices.
Horning SJ,
Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG.
Blood.
1997;
89
(3):
801-13
-
Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies.
Kusnierz-Glaz CR,
Schlegel PG, Wong RM, Schriber JR, Chao NJ, Amylon MD, Hu WW, Negrin RS, Lee Y, Blume KG, Long GD.
J Clin Oncol.
1997;
15
(1):
18-25
-
Enrichment of allogeneic CD34+ cells and T cell depletion by percoll density gradient centrifugation.
Negrin RS,
Kusnierz-Glaz C, Blume KG, Strober S.
Bone Marrow Transplant.
1996:
17 Suppl 2
S31-3
-
High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma.
Long GD,
Chao NJ, Hu WW, Negrin RS, Wong RM, Blume KG.
Cancer.
1996;
78
(12):
2502-9
-
Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
Stockerl-Goldstein KE,
Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD, Hoppe RT, Amylon MD, Brown BW, Wong RM, Blume KG.
Biol Blood Marrow Transplant.
1996;
2
(2):
76-85
-
Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy.
Negrin RS,
Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL.
Blood.
1996;
87
(10):
4076-81
-
Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
Chao NJ,
Parker PM, Niland JC, Wong RM, Dagis A, Long GD, Nademanee AP, Negrin RS, Snyder DS, Hu WW, Gould KA, Tierney DK, Zwingenberger K, Forman SJ, Blume KG.
Biol Blood Marrow Transplant.
1996;
2
(2):
86-92
-
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox SJ,
Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-López A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Levy R.
Clin Cancer Res.
1996;
2
(3):
457-70
-
A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma.
Chao NJ,
Kastrissios H, Long GD, Negrin RS, Horning SJ, Wong RM, Blaschke TF, Blume KG.
Cancer.
1995;
75
(6):
1354-9
-
Effects of granulocyte colony-stimulating factor therapy on in vitro hemopoiesis in myelodysplastic syndromes.
Nagler A,
MacKichan ML, Negrin RS, Donlon T, Greenberg PL.
Leukemia.
1995;
9
(1):
30-9
-
Enrichment of bone marrow and blood progenitor (CD34+) cells by density gradients with sufficient yields for transplantation.
Schriber JR,
Dejbakhsh-Jones S, Kusnierz-Glaz CR, Ginzton N, Still B, Negrin RS, Greenberg P, Strober S.
Exp Hematol.
1995;
23
(9):
1024-9
-
Is nitrous oxide safe for bone marrow harvest?
Lederhaas G,
Brock-Utne JG, Negrin RS, Riley E, Brodsky JB.
Anesth Analg.
1995;
80
(4):
770-2
-
Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
Long GD,
Negrin RS, Hoyle CF, Kusnierz-Glaz CR, Schriber JR, Blume KG, Chao NJ.
Cancer.
1995;
76
(5):
860-8
-
Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
Negrin RS,
Kusnierz-Glaz CR, Still BJ, Schriber JR, Chao NJ, Long GD, Hoyle C, Hu WW, Horning SJ, Brown BW.
Blood.
1995;
85
(11):
3334-41
-
Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells.
Mehta BA,
Schmidt-Wolf IG, Weissman IL, Negrin RS.
Blood.
1995;
86
(9):
3493-9
-
A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
Lu PH,
Negrin RS.
J Immunol.
1994;
153
(4):
1687-96
-
A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
Chao NJ,
Schriber JR, Long GD, Negrin RS, Catolico M, Brown BW, Miller LL, Blume KG.
Blood.
1994;
83
(10):
2823-8
-
Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations.
Negrin RS,
Pesando J.
J Clin Oncol.
1994;
12
(5):
1021-7
-
Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ,
Negrin RS, Chao JC, Long GD, Hoppe RT, Blume KG.
J Clin Oncol.
1994;
12
(12):
2552-8
-
Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation.
Schriber JR,
Chao NJ, Long GD, Negrin RS, Tierney DK, Kusnierz-Glaz C, Lucas KS, Blume KG.
Blood.
1994;
84
(5):
1680-4
-
Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
Blume KG,
Long GD, Negrin RS, Chao NJ, Kusnierz-Glaz C, Amylon MD.
Bone Marrow Transplant.
1994:
14 Suppl 4
S9-10
-
The role of N-linked carbohydrate residues in lymphokine-activated killer cell-mediated cytolysis.
Mehta BA,
Collard HR, Negrin RS.
Cell Immunol.
1994;
155
(1):
95-110
-
Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia.
Chao NJ,
Stein AS, Long GD, Negrin RS, Amylon MD, Wong RM, Forman SJ, Blume KG.
Blood.
1993;
81
(2):
319-23
-
Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
Chao NJ,
Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM.
N Engl J Med.
1993;
329
(17):
1225-30
-
Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy.
Chao NJ,
Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM, Horning SJ, Brown SL, Miller L, Blume KG.
Blood.
1993;
81
(8):
2031-5
-
Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
Schmidt-Wolf IG,
Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS.
Exp Hematol.
1993;
21
(13):
1673-9
-
The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow.
Schriber JR,
Negrin RS, Chao NJ, Long GD, Horning SJ, Blume KG.
Leukemia.
1993;
7
(10):
1491-5
-
Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin.
Negrin RS,
Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL.
Blood.
1993;
82
(3):
737-43
-
Use and toxicity of the colony-stimulating factors.
Schriber JR,
Negrin RS.
Drug Saf.
1993;
8
(6):
457-68
-
Dynamic assessment of quality of life after autologous bone marrow transplantation.
Chao NJ,
Tierney DK, Bloom JR, Long GD, Barr TA, Stallbaum BA, Wong RM, Negrin RS, Horning SJ, Blume KG.
Blood.
1992;
80
(3):
825-30
-
In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation.
Schmidt-Wolf IG,
Aihara M, Negrin RS, Blume KG, Chao NJ.
Transfusion.
1992;
32
(1):
42-5
-
The use of colony stimulating factors in clinical bone marrow transplantation.
Negrin RS,
Greenberg PL.
Curr Opin Immunol.
1992;
4
(5):
567-70
-
Therapy of hematopoietic disorders with recombinant colony-stimulating factors.
Negrin RS,
Greenberg PL.
Adv Pharmacol.
1992:
23
263-96
-
Use of the polymerase chain reaction for the detection of tumor cell involvement of bone marrow and peripheral blood: implications for purging.
Negrin RS,
J Hematother.
1992;
1
(4):
361-8
-
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
Horning SJ,
Chao NJ, Negrin RS, Hoppe RT, Kwak LW, Long GD, Stallbaum B, O'Connor P, Blume KG.
Ann Oncol.
1991:
2 Suppl 1
47-50
-
Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG,
Negrin RS, Kiem HP, Blume KG, Weissman IL.
J Exp Med.
1991;
174
(1):
139-49
-
Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging.
Negrin RS,
Kiem HP, Schmidt-Wolf IG, Blume KG, Cleary ML.
Blood.
1991;
77
(3):
654-60
-
Bone marrow transplantation for hematologic malignancies: the Stanford experience.
Chao NJ,
Amylon MD, Long GD, Negrin RS, Hoppe RT, Horning SJ, Blume KG.
Clin Transpl.
1990:
157-63
-
Effects of CSFs in preleukemia.
Greenberg PL,
Negrin R, Nagler A.
Bone Marrow Transplant.
1990:
6 Suppl 1
121-6
-
Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor.
Greenberg P,
Negrin R, Nagler A, Vincent M, Donlon T.
Int J Cell Cloning.
1990:
8 Suppl 1
293-300; discussion 300-2
-
Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes.
Nagler A,
Ginzton N, Negrin R, Bang D, Donlon T, Greenberg P.
Leukemia.
1990;
4
(3):
193-202
-
Effects of treatment of myelodysplastic syndromes with recombinant human granulocyte colony stimulating factor.
Greenberg P,
Negrin R, Nagler A, Souza L, Donlon T.
Prog Clin Biol Res.
1990:
338
151-61
-
Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF.
Nagler A,
Binet C, Mackichan ML, Negrin R, Bangs C, Donlon T, Greenberg P.
Blood.
1990;
76
(7):
1299-307
-
Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor.
Negrin RS,
Haeuber DH, Nagler A, Kobayashi Y, Sklar J, Donlon T, Vincent M, Greenberg PL.
Blood.
1990;
76
(1):
36-43
-
The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes.
Greenberg PL,
Negrin R, Nagler A.
Cancer Surv.
1990;
9
(1):
199-212
-
Lymphokine-activated killer cell activity after cryopreservation.
Schmidt-Wolf IG,
Aihara M, Negrin RS, Blume KG, Chao NJ.
J Immunol Methods.
1989;
125
(1-2):
185-9
-
Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.
Negrin RS,
Haeuber DH, Nagler A, Olds LC, Donlon T, Souza LM, Greenberg PL.
Ann Intern Med.
1989;
110
(12):
976-84
-
Nasal continuous positive airway pressure in atelectasis.
Duncan SR,
Negrin RS, Mihm FG, Guilleminault C, Raffin TA.
Chest.
1987;
92
(4):
621-4
Navigation for This Section: Stanford Hospital & Clinics
Additional Links: Hospital Services
FIND A PHYSICIAN
Help